Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles
Copyright © 2016 Elsevier Inc. All rights reserved..
Ischemic stroke is a leading cause of disability and death worldwide. Current drug treatment for stroke remains inadequate due to the existence of the blood-brain barrier. We proposed an innovative nanotechnology-based autocatalytic targeting approach, in which the blood-brain barrier modulator lexiscan is encapsulated in nanoparticles to enhance blood-brain barrier permeability and autocatalytically augment the brain stroke-targeting delivery efficiency of chlorotoxin-anchored nanoparticles. The nanoparticles efficiently and specifically accumulated in the brain ischemic microenvironment and the targeting efficiency autocatalytically increased with subsequent administrations. When Nogo-66 receptor antagonist peptide NEP1-40, a potential therapeutic agent for ischemic stroke, was loaded, nanoparticles significantly reduced infarct volumes and enhanced survival. Our findings suggest that the autocatalytic targeting approach is a promising strategy for drug delivery to the ischemic microenvironment inside the brain. Nanoparticles developed in this study may serve as a new approach for the clinical management of stroke.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nanomedicine : nanotechnology, biology, and medicine - 12(2016), 7 vom: 01. Okt., Seite 1833-1842 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Liang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2XLN4Y044H |
|---|
| Anmerkungen: |
Date Completed 02.10.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nano.2016.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM259022691 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM259022691 | ||
| 003 | DE-627 | ||
| 005 | 20231224190303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nano.2016.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0863.xml |
| 035 | |a (DE-627)NLM259022691 | ||
| 035 | |a (NLM)27039220 | ||
| 035 | |a (PII)S1549-9634(16)30018-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Liang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Elsevier Inc. All rights reserved. | ||
| 520 | |a Ischemic stroke is a leading cause of disability and death worldwide. Current drug treatment for stroke remains inadequate due to the existence of the blood-brain barrier. We proposed an innovative nanotechnology-based autocatalytic targeting approach, in which the blood-brain barrier modulator lexiscan is encapsulated in nanoparticles to enhance blood-brain barrier permeability and autocatalytically augment the brain stroke-targeting delivery efficiency of chlorotoxin-anchored nanoparticles. The nanoparticles efficiently and specifically accumulated in the brain ischemic microenvironment and the targeting efficiency autocatalytically increased with subsequent administrations. When Nogo-66 receptor antagonist peptide NEP1-40, a potential therapeutic agent for ischemic stroke, was loaded, nanoparticles significantly reduced infarct volumes and enhanced survival. Our findings suggest that the autocatalytic targeting approach is a promising strategy for drug delivery to the ischemic microenvironment inside the brain. Nanoparticles developed in this study may serve as a new approach for the clinical management of stroke | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autocatalytic targeting | |
| 650 | 4 | |a Blood–brain barrier | |
| 650 | 4 | |a Chlorotoxin | |
| 650 | 4 | |a Lexiscan | |
| 650 | 4 | |a Nanoparticles | |
| 650 | 4 | |a Stroke | |
| 650 | 7 | |a Adenosine A2 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a regadenoson |2 NLM | |
| 650 | 7 | |a 2XLN4Y044H |2 NLM | |
| 700 | 1 | |a Cai, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Daofeng |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Derek K |e verfasserin |4 aut | |
| 700 | 1 | |a Gou, Xingchun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zeming |e verfasserin |4 aut | |
| 700 | 1 | |a Strittmatter, Stephen M |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zuoheng |e verfasserin |4 aut | |
| 700 | 1 | |a Sheth, Kevin N |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jiangbing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine : nanotechnology, biology, and medicine |d 2005 |g 12(2016), 7 vom: 01. Okt., Seite 1833-1842 |w (DE-627)NLM16062021X |x 1549-9642 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2016 |g number:7 |g day:01 |g month:10 |g pages:1833-1842 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nano.2016.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2016 |e 7 |b 01 |c 10 |h 1833-1842 | ||